These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35099758)

  • 1. Staging Disease Severity Using the Alzheimer's Disease Composite Score (ADCOMS): A Retrospective Data Analysis.
    Tahami Monfared AA; Houghton K; Zhang Q; Mauskopf J;
    Neurol Ther; 2022 Mar; 11(1):413-434. PubMed ID: 35099758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Clinical Meaningfulness of the Alzheimer's Disease Composite Score (ADCOMS) Tool.
    Tahami Monfared AA; Lenderking WR; Savva Y; Ladd MK; Zhang Q;
    Neurol Ther; 2022 Sep; 11(3):1085-1100. PubMed ID: 35513767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.
    Wang J; Logovinsky V; Hendrix SB; Stanworth SH; Perdomo C; Xu L; Dhadda S; Do I; Rabe M; Luthman J; Cummings J; Satlin A
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):993-9. PubMed ID: 27010616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
    Abdullah L; Crawford F; Tsolaki M; Börjesson-Hanson A; Olde Rikkert M; Pasquier F; Wallin A; Kennelly S; Ait-Ghezala G; Paris D; Hendrix S; Blennow K; Lawlor B; Mullan M
    Front Neurol; 2020; 11():149. PubMed ID: 32210906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study.
    O'Bryant SE; Waring SC; Cullum CM; Hall J; Lacritz L; Massman PJ; Lupo PJ; Reisch JS; Doody R;
    Arch Neurol; 2008 Aug; 65(8):1091-5. PubMed ID: 18695059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
    Dhadda S; Kanekiyo M; Li D; Swanson CJ; Irizarry M; Berry S; Kramer LD; Berry DA
    Alzheimers Res Ther; 2022 Dec; 14(1):182. PubMed ID: 36482412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Operational Determination of Subjective Cognitive Decline, Mild Cognitive Impairment, and Dementia Using Sum of Boxes of the Clinical Dementia Rating Scale.
    Yang YW; Hsu KC; Wei CY; Tzeng RC; Chiu PY
    Front Aging Neurosci; 2021; 13():705782. PubMed ID: 34557083
    [No Abstract]   [Full Text] [Related]  

  • 14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity of the Clinical Dementia Rating Scale Sum of Boxes in Staging and Detection of Cognitive Impairment in Mexican Americans.
    Julayanont P; DeToledo JC
    J Geriatr Psychiatry Neurol; 2022 Jan; 35(1):128-134. PubMed ID: 33261535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database.
    O'Bryant SE; Lacritz LH; Hall J; Waring SC; Chan W; Khodr ZG; Massman PJ; Hobson V; Cullum CM
    Arch Neurol; 2010 Jun; 67(6):746-9. PubMed ID: 20558394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation study of the Alzheimer's Disease Assessment Scale-Cognitive Subscale for people with mild cognitive impairment and Alzheimer's disease in Chinese communities.
    Yang H; Cheng Z; Li Z; Jiang Y; Zhao J; Wu Y; Gu S; Xu H
    Int J Geriatr Psychiatry; 2019 Nov; 34(11):1658-1666. PubMed ID: 31347192
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.